M40 (M 40)

has the same N-terminal amino acid sequence as galanin 1-13; binds to neuronal galanin receptor, thereby making it a galanin antagonist

Also Known As:

M 40; Pro-Pro-2-(Ala-Leu)-Ala-galanin (1-13)-amide; galanin (1-13)-amide, Pro-Pro-(Ala-Leu)(2)-Ala-; galanin (1-13)-amide, prolyl-prolyl-(alanyl-leucyl)(2)-alanyl-; galanin(1-13)-Pro-Pro-(Ala-Leu)(2)-Ala amide

Networked: 72 relevant articles (4 outcomes, 6 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Amino Acids, Peptides, and Proteins: 1
- Proteins: 484843
  - Nerve Tissue Proteins: 2
    - Neuropeptides: 6772
      - Galanin: 931
        M40: 72
- Peptides: 82426
  - Neuropeptides: 6772
    - Galanin: 931
      - M40: 72
  - Peptide Fragments: 373
    - M40: 72

Experts

1.	Harty, Ronald N: 3 articles (01/2022 - 11/2012)
2.	Freedman, Bruce D: 2 articles (01/2022 - 01/2016)
3.	Ruthel, Gordon: 2 articles (01/2022 - 01/2016)
4.	Erevik, Eilin Kristine: 1 article (06/2022)
5.	Leino, Tony: 1 article (06/2022)
6.	Mentzoni, Rune Aune: 1 article (06/2022)
7.	Pallesen, Ståle: 1 article (06/2022)
8.	Smith, Otto R F: 1 article (06/2022)
9.	Syvertsen, André: 1 article (06/2022)
10.	Barrett, Emma: 1 article (01/2022)

Related Diseases

1.	Myocardial Infarction 06/01/1992 - "Supranormal Ig levels (A > or = 300, G > or = 1,200) or subnormal Ig levels (M < 40 mg/100 ml) were seen in patients with one or several risk factors (diabetes mellitus, alcohol abuse) or a history of previous myocardial infarction. " 02/01/2003 - "At the baseline, Group L had a significantly lower LVEF (H 55+/-7 vs. M 40+/-3 vs. L 30+/-3%, P<0.05), significantly greater LVDd (49+/-6 vs. 52+/-7 vs. 56+/-6 mm, P<0.05), and a higher incidence of anterior infarction (P<0.01) compared with Groups H and M, whereas there were no difference in age, sex, coronary risk factors, the incidence of multivessel disease, prior myocardial infarction, peak WR or peak VO(2) among the three groups. "
2.	Pancreatitis 01/01/2010 - "Galanin receptor antagonist m35 but not m40 or c7 ameliorates cerulein-induced acute pancreatitis in mice." 01/01/2010 - "We compared the galanin antagonists C7, M35, M40 and galantide, for their ability to ameliorate acute pancreatitis (AP). "
3.	Infarction (Infarctions) 02/01/2003 - "At the baseline, Group L had a significantly lower LVEF (H 55+/-7 vs. M 40+/-3 vs. L 30+/-3%, P<0.05), significantly greater LVDd (49+/-6 vs. 52+/-7 vs. 56+/-6 mm, P<0.05), and a higher incidence of anterior infarction (P<0.01) compared with Groups H and M, whereas there were no difference in age, sex, coronary risk factors, the incidence of multivessel disease, prior myocardial infarction, peak WR or peak VO(2) among the three groups. "
4.	Fibrosis (Cirrhosis) 10/01/2015 - "Compared with rats injected with saline, M40 effectively improved cardiac function of contraction; decreased BNP, IL-6, and HW/BW (all P < 0.05); attenuated cardiac fibrosis; and upregulated SERCA2 (P < 0.05). "
5.	Acidosis 09/01/2017 - "The use of the FO and M40 treatments did not change most of the rumen fermentation variables, especially in the first week after abrupt transition, when the M30 treatment provided higher protection against acidosis."

Related Drugs and Biologics

1.	Galanin Receptors (Galanin Receptor)
2.	L 30 (L-30)
3.	Interleukin-6 (Interleukin 6)
4.	Ceruletide
5.	Dextrans (Dextran)
6.	Vincristine (Oncovin)
7.	Tubulin
8.	Methotrexate (Mexate)
9.	Gelatin
10.	Cisplatin (Platino)

Related Therapies and Procedures

1.	Respiratory Protective Devices (Gas Mask)
2.	Intravenous Infusions
3.	Hemodilution
4.	Therapeutics
5.	Telescopes